Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis : A Narrative Review

Marvin J. Fritzler, Chelsea Bentow, Lorenzo Beretta, Boaz Palterer, Janire Perurena-Prieto, María Teresa Sanz-Martínez, Alfredo Guillén-Del-Castillo, Ana Marín-Sánchez, Vicent Fonollosa Pla, Eduardo Luis Callejas Moraga, Carmen Pilar Simeón-Aznar, Michael Mahler

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

4 Cites (Scopus)

Resum

Anti-nuclear (ANA) are present in approximately 90% of systemic sclerosis (SSc) patients and are key biomarkers in supporting the diagnosis and determining the prognosis of this disease. In addition to the classification criteria autoantibodies for SSc [i.e., anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA polymerase III], other autoantibodies have been associated with important SSc phenotypes. Among them, anti-U11/U12 ribonucleoprotein (RNP) antibodies, also known as anti-RNPC-3, were first reported in a patient with SSc, but very little is known about their association and clinical utility. The U11/U12 RNP macromolecular complex consists of several proteins involved in alternative mRNA splicing. More recent studies demonstrated associations of anti-anti-U11/U12 antibodies with SSc and severe pulmonary fibrosis as well as with moderate to severe gastrointestinal dysmotility. Lastly, anti-U11/U12 autoantibodies have been strongly associated with malignancy in SSc patients. Here, we aimed to summarize the knowledge of anti-U11/U12/RNPC-3 antibodies in SSc, including their seroclinical associations in a narrative literature review.
Idioma originalEnglish
RevistaDiagnostics
Volum13
DOIs
Estat de la publicacióPublicada - 2023

Fingerprint

Navegar pels temes de recerca de 'Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis : A Narrative Review'. Junts formen un fingerprint únic.

Com citar-ho